Cancer treatment maker Legend Biotech Corp. (LEGN.US) announced its appointment of a new CEO on Tuesday, a month and a half after the sudden departure of its longtime chief executive caused its shares to tumble.
The company named Ingrid Zhang as its new chief executive, replacing Alan Bash, who was filling the position on an interim basis after the late July resignation of Huang Ying. Before his departure, Huang had served as Legend’s CEO since September 2020. Bash is president of the unit that oversees the company’s blockbuster cancer treatment, Carvykti.
Zhang most recently served as chief commercial officer for the international division of drug giant Novartis (NOVN.SW). Before that she held leadership positions at other major drug companies, including AstraZeneca (AZN.L) and Pfizer (PFE.US).
Legend Biotech’s revenue rose 52% to $387.5 million in the second quarter from $255.1 million a year earlier. It recorded a net profit of $33.2 million in the latest three-month period, reversing a loss of $125.4 million a year earlier.
Legend Biotech’s stock fell 4.6% to close at $17.67 on Tuesday after the announcement. The stock is down about 20% since the company announced Huang Ying’s departure in July.
By Doug Young
To subscribe to Bamboo Works weekly free newsletter, clickhere
Related Articles
RELATED ARTICLES
-
Legend Bio CEO resigns, shares tumble
- BRIEF: Legend Biotech’s revenue jumps on growing momentum for cancer treatment
-
Cancer drug sales power up Kelun-Biotech’s profit engine
6990.HK
-
iQiyi names Tian Ying as new CFO
IQ.US
- Luzhu Biotech braces for make-or-break launch of shingles shot
- Cancer screening company faces tough IPO test as market cools
-
TransThera completes late-stage trial enrollment for Tinengotinib cancer drug
2617.HK
